Background: Quinolone resistance is a major global clinical problem. It primarily emerges in microbiota under selective pressure. Studies evaluating the incidence and risk factors for carrying quinolone-resistant bacteria in hospitalized patients treated with fluoroquinolones (FQs) are lacking.
Introduction
Resistance to fluoroquinolones (FQs) mainly emerges in the human microbiota, which are major natural reservoirs for bacterial resistance, 1, 2 leading to infections with antibiotic-resistant commensals and the risk of inter-and intra-species genetic exchanges. 1, 3, 4 Drug regimens and doses are established to limit the emergence of resistance in infectious foci, but the consequences on microbiota are not taken into account. Yet FQs penetrate particularly well in microbiota, reaching high local concentrations, 5 -9 leading to profound effects on microbiota and the clinically relevant bacteria that compose them, such as Escherichia coli in the gut, staphylococci in the nasal and skin microbiota and oral streptococci. 2 To date, few data exist concerning the impact of FQ therapy in terms of emergence of resistance to quinolones in the microbiota of ill patients and in particular in hospitalized patients, who are at particularly high risk of carrying and transmitting resistant organisms. 10, 11 Furthermore, the impact of quinolone therapy on all three main human microbiotas studied together in the same subjects has never been assessed. The aim of this work was to determine the impact of FQ treatment on the microbiota of hospitalized patients by determining the rates of and potential risk factors associated with the emergence of resistance to FQs in patients treated or not with FQs during their hospital stay.
Materials and methods

Patients and study design
We conducted a prospective cohort study including patients admitted in two tertiary care teaching hospitals (500 beds each) in Paris, France from October 2010 to July 2012. Adult patients hospitalized for at least 24 h and receiving an FQ during their hospital stay could be included if they had not received an FQ in the previous month and gave informed consent. A reference group of patients was included to measure the risk of emergence of resistance to FQs due to hospitalization alone. Reference patients were adults who did not receive FQ during their hospital stay or in the previous month and were hospitalized for ,48 h. The first 120 subjects corresponding to these criteria were included in the reference group. They were matched with FQ-treated patients by date of admission (+7 days), age (+years) and study centre. Each subject could only be enrolled once. This work was approved by the French National Institutional Review Board (IRB 00008522; clinical trial: NCT01209247).
Sample collection
Three swabs were performed by the hospital staff at each visit: a nasal, an oropharyngeal and a rectal swab. Clinical data were collected on the first visit, including demographics, size and weight, medical history, comorbidities, history of previous antibiotic consumption, history of previous hospitalizations, current antibiotic consumption and reason for current hospitalization. At each visit, details of FQ treatment and other antibiotics were collected: reason for administration; daily dosing regimen; route of administration; and results of the microbiology assays. FQ-treated patients had three visits: before or in the 24 h following the beginning of FQ treatment (T0); at the end of treatment (T1) (+3 days); and 30 days after the end of treatment (T2) (+7 days). Patients in the reference group received two visits: upon inclusion (Ta) and before discharge (Tb).
Microbiological methods
For each patient, the three swabs were separately discharged in 1 mL of brain heart infusion broth with glycerol, and stored at 2808C. For each site, specific target species were chosen because they are present in most subjects, are frequently involved in invasive and opportunistic infections and are recognized sources of horizontal transfer within the microbiome:
4,12 E. coli for the faecal microbiota, coagulase-negative staphylococci (CoNS) and Staphylococcus aureus for the nasal microbiota and a-haemolytic streptococci for the oropharyngeal microbiota. Rectal samples were plated on three Drigalski plates (Pasteur Diagnostics, Paris, France), one containing no antibiotics, one with 16 mg/L of nalidixic acid and one with 1 mg/L of ciprofloxacin. Nasal samples were plated on two Chapman agar plates (bioMérieux, Marcy-l'Étoile, France) with and without 1 mg/L of ciprofloxacin. Oropharyngeal samples were plated on two Columbia colistin/nalidixic acid agar plates (15 mg/L of nalidixic acid, 10 mg/L of colistin and 5% blood; bioMé rieux) with and without 4 mg/L of levofloxacin. If cultures were positive on the FQ-containing plates, three colonies were randomly picked, conventional techniques were used to identify E. coli, CoNS, S. aureus and a-haemolytic streptococci, and MICs of FQs were determined by the agar dilution method. Resistance was defined according to the breakpoints established by EUCAST (http://www.eucast.org). First levels of quinolone resistance in E. coli were screened using resistance to nalidixic acid (MIC of .16 mg/L) as a surrogate marker. 5 
Statistical methods
Patient characteristics were compared using x 2 or Fisher's exact test for categorical variables or Student's t-and Wilcoxon rank-sum tests for continuous variables, when appropriate. Prevalence of resistance to quinolones in each microbiota and incidence of resistance at T1 and T2 for FQ-treated patients, and Tb for untreated patients, were estimated for each of the three microbiota. Incidence of resistance was defined by the ratio of the number of new cases of resistance between T0, T1 and T2 and the number of patients with no resistance at T0. To identify risk factors for the emergence of resistance among the FQ-exposed subjects, associations of variables [age, sex, body mass index (BMI), hospital ward, Charlson comorbidity score, immunosuppression, performance status, previous hospitalizations, coming from home before hospitalization, previous antibiotic treatment, current antibiotic treatment, type of FQ received, duration of FQ treatment, total FQ dose received and duration of hospital stay] were assessed by univariate analysis, comparing patients with resistance at T2 with those without resistance at T2 among patients with no resistance at T0, each microbiota being studied separately. All variables associated with quinolone resistance at a P value of ,0.2 in the univariate analysis were included in a multivariate analysis in a stepwise manner to construct the final model using a logistic regression model. A P value ,0.05 was considered to be significant. Analysis was done per protocol. All analyses were performed using the SAS software version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Altogether 570 patients were included: 451 patients receiving FQs (FQ-treated group) and 119 patients not receiving FQs (reference group) (see study flow chart; Figure 1 ). Characteristics of patients are reported in Table 1 . The median duration of hospital stay was 13 days (range 7-24) in the FQ-treated group and 7 days (range 5 -8) in the reference group (P, 0.001). The main reasons for receiving FQs were urinary tract infections (37.5%), abdominal infections (13.3%), prophylactic treatment (12.6%), respiratory tract infections (8.9%), bone and joint infections (6.2%) and skin and soft tissue infections (4.9%). Ofloxacin was the most prescribed FQ (51.6%) followed by ciprofloxacin (36.4%), levofloxacin (10.9%), norfloxacin (4%) and moxifloxacin (0.6%). Median duration of FQ treatment was 9 days (range 5 -18 days).
Initial carriage rates of resistance to FQs at inclusion were not different (Table 1 ). However, rates of emergence of FQ resistance at the end of the study among patients initially not carrying resistance were significantly higher in the FQ-treated group than for the reference group for E. coli, CoNS and S. aureus, but not for a-haemolytic streptococci (Table 2) . No difference was found in rates of emergence of resistance by drug regimen (Table 3) .
For each target species, FQ-treated patients carrying resistant strains at the end of the study (T2) were compared with those carrying only susceptible strains in order to identify potential risk factors for the carriage of resistant strains after FQ exposure. In the univariate analysis, male sex (P ¼ 0.04), a lower BMI (P ¼ 0.04), having been hospitalized in the previous year (P¼0.03) and having received other antibiotics between T0 and T1 (P¼0.04) or between T1 and T2 (P ¼ 0.05) were significantly associated with the risk of carrying FQ-resistant E. coli. For CoNS and a-haemolytic streptococci, no factor was identified either in the univariate or multivariate analysis with the fact of carrying FQ-resistant organisms at the end of the study. For S. aureus, a longer duration of FQ treatment was associated with carriage of resistance in the univariate analysis (P ¼0.01). Results of the multivariate analyses are summarized in Table 4 .
Additionally, in order to determine whether duration of hospital stay was associated with the risk of emergence of resistance independently from FQ treatment, we compared patients carrying de Lastours et al.
resistant strains with those carrying only susceptible strains at the end of the study (T2 for FQ-treated subjects and Tb for controls), whether or not they were receiving FQ. Among the 446 patients from both groups who had not been lost to follow-up, duration of hospital stay did not significantly differ between patients carrying resistant strains and those carrying susceptible strains (21 days for FQ-resistant versus 17 days for FQ-susceptible E. coli; 16 versus 20 days for CoNS; 15 versus 17 days for S. aureus; and 14 versus 17 days for streptococci, respectively).
Discussion
In a population in which the initial prevalence of carriage of FQ-resistant bacteria in the microbiota was high, we found that exposure to FQs during hospitalization was associated with high risks of carriage of FQ resistance in all three microbiota at the end of treatment. This finding is of concern as we have previously shown, concerning E. coli, that the resistant strains that manage to colonize the human gut after FQ exposure are well adapted to commensalism and may therefore remain for a prolonged period. 13 An important aim in clinical practice is to identify patients at risk of acquiring resistance to FQs in their microbiota when treated with FQs during hospitalization. We did not find here that the type of FQ had any impact on the risk of the emergence of resistance. Since most patients received either ciprofloxacin or ofloxacin, we are confident that no difference in the risk of the emergence of resistance was found between these two molecules. Duration of Emergence of quinolone resistance in microbiota 3395 JAC de Lastours et al.
FQ treatment did not appear to be a significant risk factor for developing resistance either, except for S. aureus and only in the univariate analysis. This may be explained by the fact that FQs have a rapid impact on microbiotas, within 3 -4 days after exposure; 14 in addition, ciprofloxacin, for example, may be found at high concentrations in the stools up to 10 days after a single dose. 7 Therefore, even patients treated for a few days will experience major selective pressure on their microbiota, regardless of the duration of treatment. Similarly, the duration of hospital stay did not seem to impact the risk of emergence of resistance in any of the microbiota, suggesting that acquisition of FQresistant strains probably occurs quickly after hospital admission. It is noteworthy that host factors (immunosuppression, abnormal performance status) were associated with resistance. Our hypothesis is that the capacity of the gut microbiota to effectively resist colonization by exogenous resistant organisms (known as 'colonization resistance' 15 ) may be hampered in frail and immunosuppressed subjects who are particularly dependent on nursing staff. Another important issue is the impact of another antibiotic therapy on the selection of FQ resistance in microbiota. Indeed, having received another antibiotic than an FQ appears to be a risk factor for carrying resistant E. coli in the gut (in the univariate analysis), as previously found by others, 16 yet an independent protective factor against carrying resistant S. aureus in the nares. In the gut, co-prescription of other antibiotics will mainly co-select resistance due to the immense reservoir of resistance genes. Also, other antibiotics may disturb the colonization-resistance capacities of the microbiota, potentially allowing colonization by resistant strains. Conversely, in the nasal microbiota, a smaller size of bacterial inoculum, on the one hand, and lower impact, if any, of colonization resistance on the other probably explain why receiving other antibiotics decreased the risk of carriage of resistant S. aureus. The use of antibiotic combinations, which may be effective to prevent the emergence of resistance in infectious foci, may therefore not necessarily have the same effect in microbiota.
Rates of emergence of resistance and risk factors associated with the emergence of resistance differed from one microbiota to another. In particular, no common risk factor for the emergence of resistance was found between the different microbiota. Furthermore, whereas emergence of resistance was higher in subjects receiving FQs for E. coli and staphylococci, FQ treatment did not seem to affect the risk of acquiring FQ-resistant oral streptococci during a hospital stay, as rates were not different whether subjects were receiving FQs or not. We have previously found that each microbiota behaves independently, to the point that carrying resistance in the three target species at once is no more than random. 10 Indeed, even though each microbiota in the same patient is theoretically submitted to the same exogenous selective pressures, local FQ concentrations vary widely from one microbiota to another, as well as local antibiotic clearance dynamics. 5 -9 Moreover, each microbiota is submitted to different external (horizontal transmission of resistant strains through interindividual contacts, food, hand-borne transmission or others) 17 -20 and internal influences (genetic exchanges between and among species). 4, 21 Therefore, each microbiota needs to be addressed separately, and data from one microbiota cannot be extrapolated to others.
Emergence of FQ resistance was not limited to patients treated with FQs. Indeed, high rates of emergence of resistance also occurred in the reference group, confirming that horizontal transmission of resistant strains among hospitalized patients occurs frequently, favoured by the high prevalence of resistance to FQs upon admission in this population, which was prone to the acquisition of nosocomial bacteria because of its medical history. This confirms previous findings from our group suggesting Emergence of quinolone resistance in microbiota 3397 JAC that exogenous acquisition of resistance strains prevails. 22, 23 Although this group was not designed to be a control group, initial carriage rates of resistant organisms were not different between the two groups. No difference was found between FQ-treated and reference patients concerning the emergence of resistance in oral streptococci, whereas emergence of resistance was significantly higher in the FQ-treated group for E. coli and nasal staphylococci. Some limits to this work need to be addressed. First, the population studied here harboured a high prevalence of FQ resistance at baseline and results from this work may therefore not be extrapolated to other populations. However, the rates found here were similar to those in a previous study by our team conducted in one of the same hospitals, 10 and work conducted elsewhere found rates of intestinal colonization by FQ-resistant E. coli ranging from 5% to 50% in long-term care facilities 11,24 -27 and similar rates of emergence of resistance in hospitalized patients. 16 Similar rates of FQ resistance in oral streptococci and nasal staphylococci have also been reported. 28 -30 Second, the reference group was not comparable in many aspects to the FQ-treated population. Indeed, this was not a randomized trial since the reference group did not require any FQ treatment. Therefore, many differences were found with the FQ-treated The P values of Hosmer -Lemeshow goodness-of-fit tests were 0.8, 0.73, 0.74 and 0.11 for E. coli, CoNS, S. aureus and a-haemolytic streptococci, respectively (large P values indicate a good fit of the model). a b-Lactams, 64%; glycopeptides, 9%; aminoglycosides, 10%; another course of FQ, 22.5%; other, 8% (patients may have received more than one antibiotic).
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group, which was expected. This reference group, however, adds important insight in the mechanisms involved in the acquisition of FQ resistance during hospitalization since high rates of acquisition of FQ resistance were observed in this group despite reduced duration of hospital stay, comorbidities, previous hospitalizations and antibiotic consumption rates. Finally, a relatively high rate of dropouts occurred. Yet no major difference was found between subjects not available for T1 sampling and those available, in particular in terms of FQ resistance carriage, apart from the fact that subjects who were not available at T1 were more likely to have been hospitalized in the previous year than those who were available.
In conclusion, hospitalization accounts for high rates of emergence of resistance to FQs in clinically relevant bacteria from microbiota, and FQ treatment further increases the risk of emergence of resistance. Host factors outweighed treatment or hospitalization characteristics as no factor linked to the FQ regimen, duration of therapy or duration of hospital stay was associated with the emergence of resistance in microbiota. Therefore, no simple intervention seems to be able to limit the spread of FQ-resistant organisms in the microbiota of hospitalized patients. Limiting FQ consumption, in particular in hospitals, as well as patient-to-patient transmission of resistant bacteria should be further encouraged until we know more about the behaviour of human microbiota.
